Hyloris (HYL) | Financial Analysis & Statements
Hyloris Pharmaceuticals SA Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2020Income Metrics
Revenue
19.0K
Gross Profit
-70.0K
-368.42%
Operating Income
-2.4M
-12,468.42%
Net Income
-2.2M
-11,378.95%
Balance Sheet Metrics
Total Assets
37.1M
Total Liabilities
8.2M
Shareholders Equity
28.9M
Debt to Equity
0.28
Cash Flow Metrics
Operating Cash Flow
-928.0K
Free Cash Flow
2.3M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2020
Annual Income Flow
2024
Hyloris Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 8.5M | 2.1M | 900.0K | 3.1M | 175.0K |
| Cost of Goods Sold | 227.0K | 93.0K | 94.0K | 107.0K | 145.0K |
| Gross Profit | 8.2M | 2.0M | 806.0K | 3.0M | 30.0K |
| Gross Margin % | 97.3% | 95.5% | 89.6% | 96.5% | 17.1% |
| Operating Expenses | |||||
| Research & Development | 10.3M | 14.4M | 10.3M | 5.1M | 3.4M |
| Selling, General & Administrative | 6.2M | 5.5M | 3.5M | 2.9M | 2.2M |
| Other Operating Expenses | 10.0K | - | 12.0K | 5.8M | - |
| Total Operating Expenses | 16.5M | 20.0M | 13.8M | 13.7M | 5.6M |
| Operating Income | -6.4M | -15.8M | -11.5M | -10.3M | -5.6M |
| Operating Margin % | -75.3% | -759.3% | -1,278.7% | -334.2% | -3,174.9% |
| Non-Operating Items | |||||
| Interest Income | 901.0K | 869.0K | 67.0K | 32.0K | 543.0K |
| Interest Expense | 77.0K | 52.0K | 219.0K | 556.0K | 992.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -6.3M | -15.4M | -11.9M | -11.3M | -7.1M |
| Income Tax | 0 | 0 | 4.0K | 297.0K | 1.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -6.3M | -15.4M | -11.9M | -11.6M | -7.1M |
| Net Margin % | -75.0% | -736.9% | -1,322.9% | -374.0% | -4,082.9% |
| Key Metrics | |||||
| EBITDA | -4.9M | -15.0M | -12.0M | -10.6M | -5.7M |
| EPS (Basic) | €-0.23 | €-0.56 | €-0.43 | €-0.45 | €-0.33 |
| EPS (Diluted) | €-0.23 | €-0.56 | €-0.43 | €-0.45 | €-0.33 |
| Basic Shares Outstanding | 28000374 | 28000374 | 27198925 | 25832632 | 21818814 |
| Diluted Shares Outstanding | 28000374 | 28000374 | 27198925 | 25832632 | 21818814 |
Income Statement Trend
Hyloris Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 23.6M | 30.4M | 33.5M | 50.0M | 64.4M |
| Short-term Investments | - | - | 10.0M | 528.0K | 7.0K |
| Accounts Receivable | 4.9M | 3.6M | 4.1M | 2.3M | 48.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | 1.1M | 2.0M |
| Total Current Assets | 29.7M | 35.3M | 49.8M | 54.0M | 66.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 876.0K | 824.0K | 176.0K | 122.0K | 24.0K |
| Goodwill | 3.8M | 3.8M | 3.6M | 2.9M | 2.4M |
| Intangible Assets | 3.8M | 3.8M | 3.6M | 2.9M | 2.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | - | 1.0K | 1.7M | - |
| Total Non-Current Assets | 11.6M | 12.4M | 10.9M | 9.5M | 2.6M |
| Total Assets | 41.3M | 47.7M | 60.7M | 63.4M | 69.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.2M | 3.2M | 2.3M | 2.6M | 1.6M |
| Short-term Debt | 326.0K | 241.0K | 138.0K | 65.0K | 455.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | 1.0K |
| Total Current Liabilities | 7.2M | 6.8M | 5.8M | 15.0M | 2.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.5M | 1.5M | 747.0K | 109.0K | 8.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | -1.0K | - | 1.0K | - |
| Total Non-Current Liabilities | 2.0M | 1.9M | 1.0M | 410.0K | 8.0M |
| Total Liabilities | 9.2M | 8.6M | 6.8M | 15.4M | 10.1M |
| Equity | |||||
| Common Stock | 140.0K | 140.0K | 140.0K | 129.0K | 129.0K |
| Retained Earnings | -86.5M | -80.8M | -65.4M | -54.8M | -43.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 32.1M | 39.1M | 53.9M | 48.1M | 59.1M |
| Key Metrics | |||||
| Total Debt | 1.8M | 1.8M | 885.0K | 174.0K | 8.4M |
| Working Capital | 22.5M | 28.5M | 44.0M | 39.0M | 64.5M |
Balance Sheet Composition
Hyloris Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -6.3M | -15.4M | -11.9M | -11.6M | -7.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | -584.0K | 540.0K | 560.0K | 576.0K | 485.0K |
| Working Capital Changes | -1.9M | 29.0K | -865.0K | -1.6M | 1.4M |
| Operating Cash Flow | -9.6M | -15.4M | -11.9M | -12.4M | -3.8M |
| Investing Activities | |||||
| Capital Expenditures | -29.0K | -298.0K | -101.0K | -107.0K | 0 |
| Acquisitions | - | - | - | -1.3M | 0 |
| Investment Purchases | - | 0 | -10.5M | -1.2M | -10.0K |
| Investment Sales | 0 | 10.0M | 522.0K | 216.0K | 0 |
| Investing Cash Flow | -29.0K | 9.7M | -10.1M | -2.3M | -10.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 139.0K | 51.0K | 0 | - | 18.2M |
| Debt Repayment | -40.0K | 0 | -7.4M | -62.0K | -8.1M |
| Financing Cash Flow | 99.0K | 51.0K | 9.8M | -62.0K | 69.4M |
| Free Cash Flow | -7.2M | -13.6M | -13.8M | -12.3M | -5.2M |
| Net Change in Cash | -9.5M | -5.7M | -12.2M | -14.8M | 65.6M |
Cash Flow Trend
Hyloris Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-23.65
Forward P/E
10.76
Price to Book
5.70
Price to Sales
17.24
PEG Ratio
10.76
Profitability Ratios
Profit Margin
-71.71%
Operating Margin
-76.19%
Return on Equity
-21.61%
Return on Assets
-12.90%
Financial Health
Current Ratio
3.89
Debt to Equity
6.08
Beta
0.66
Per Share Data
EPS (TTM)
€-0.24
Book Value per Share
€0.96
Revenue per Share
€0.32
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HYL | 152.3M | -23.65 | 5.70 | -21.61% | -71.71% | 6.08 |
| Argenx SE | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Onward Medical N.V | 204.4M | - | 2.98 | -80.85% | 72.51% | 24.70 |
| European Medical | 20.7M | 11.14 | 1.72 | 16.43% | 3.46% | 154.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.